GeoVax Labs, Inc. (GOVX)Healthcare | Biotechnology | Smyrna, United States | NasdaqCM
1.24 USD
+0.01
(0.813%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.29 +0.05 (4.032%) ⇧ (April 17, 2026, 6:53 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:47 p.m. EDT
GOVX is currently in a highly volatile and bearish trend, with significant negative momentum. The price has been fluctuating around the 52-week low, indicating a lack of investor confidence and a weak market position. The short-term forecasting model suggests a substantial decline in price over the next 45 days, which makes it a poor candidate for short-term trading. The company's fundamentals are also weak, with negative earnings and a low price-to-book ratio, suggesting that the stock is undervalued but not in a strong position for long-term investment. Additionally, there are no dividends to consider, making it unsuitable for dividend-focused investors. Overall, the stock appears to be a high-risk investment with limited upside potential. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.400049 |
| AutoETS | 0.457195 |
| AutoARIMA | 0.459396 |
| MSTL | 0.506338 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.254 |
| Excess Kurtosis | -1.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 22.043 |
| Revenue per Share | 2.597 |
| Market Cap | 3,586,788 |
| Forward P/E | -1.44 |
| Website | https://www.geovax.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.93526316 |
| Address1 | 1,900 Lake Park Drive |
| Address2 | Suite 380 |
| All Time High | 3,266.25 |
| All Time Low | 1.137 |
| Ask | 1.26 |
| Ask Size | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 77,920 |
| Average Daily Volume3 Month | 113,940 |
| Average Volume | 113,940 |
| Average Volume10Days | 77,920 |
| Bid | 1.21 |
| Bid Size | 1 |
| Book Value | 4.13 |
| City | Smyrna |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.24 |
| Current Ratio | 2.744 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.2799 |
| Day Low | 1.21 |
| Debt To Equity | 22.043 |
| Display Name | GeoVax Labs |
| Dividend Date | 1,600,992,000 |
| Earnings Call Timestamp End | 1,774,641,600 |
| Earnings Call Timestamp Start | 1,774,641,600 |
| Earnings Timestamp | 1,773,950,400 |
| Earnings Timestamp End | 1,774,296,000 |
| Earnings Timestamp Start | 1,774,296,000 |
| Ebitda | -21,570,292 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.062 |
| Enterprise To Revenue | 0.54 |
| Enterprise Value | 1,344,215 |
| Eps Forward | -0.86 |
| Eps Trailing Twelve Months | -22.4 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 678 384 7281 |
| Fifty Day Average | 1.6704 |
| Fifty Day Average Change | -0.4304 |
| Fifty Day Average Change Percent | -0.25766283 |
| Fifty Two Week Change Percent | -93.52631 |
| Fifty Two Week High | 34.75 |
| Fifty Two Week High Change | -33.51 |
| Fifty Two Week High Change Percent | -0.9643165 |
| Fifty Two Week Low | 1.137 |
| Fifty Two Week Low Change | 0.103000045 |
| Fifty Two Week Low Change Percent | 0.090589315 |
| Fifty Two Week Range | 1.137 - 34.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,040,600,000 |
| Float Shares | 2,888,376 |
| Forward Eps | -0.86 |
| Forward P E | -1.4418604 |
| Free Cashflow | -14,717,994 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 2,489,145 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00123 |
| Held Percent Institutions | 0.07793 |
| Implied Shares Outstanding | 2,892,571 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,768,176,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia. |
| Long Name | GeoVax Labs, Inc. |
| Market | us_market |
| Market Cap | 3,586,788 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_12056751 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -21,464,772 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,586,786 |
| Number Of Analyst Opinions | 3 |
| Open | 1.26 |
| Operating Cashflow | -21,473,968 |
| Operating Margins | -8.69337 |
| Payout Ratio | 0.0 |
| Phone | 678 384 7220 |
| Post Market Change | 0.049999952 |
| Post Market Change Percent | 4.032254 |
| Post Market Price | 1.29 |
| Post Market Time | 1,776,466,412 |
| Previous Close | 1.23 |
| Price Hint | 4 |
| Price To Book | 0.30024213 |
| Price To Sales Trailing12 Months | 1.4409719 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.593 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.813007 |
| Regular Market Day High | 1.2799 |
| Regular Market Day Low | 1.21 |
| Regular Market Day Range | 1.21 - 1.2799 |
| Regular Market Open | 1.26 |
| Regular Market Previous Close | 1.23 |
| Regular Market Price | 1.24 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 88,920 |
| Return On Assets | -1.8657299 |
| Return On Equity | -4.83786 |
| Revenue Growth | -1.0 |
| Revenue Per Share | 2.597 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,892,570 |
| Shares Percent Shares Out | 0.0908 |
| Shares Short | 252,981 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 210,698 |
| Short Name | GeoVax Labs, Inc. |
| Short Percent Of Float | 0.090900004 |
| Short Ratio | 3.88 |
| Source Interval | 15 |
| State | GA |
| Symbol | GOVX |
| Target High Price | 350.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 190.83333 |
| Target Median Price | 212.5 |
| Total Cash | 3,085,741 |
| Total Cash Per Share | 1.067 |
| Total Debt | 843,170 |
| Total Revenue | 2,489,145 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -22.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.9193 |
| Two Hundred Day Average Change | -8.6793 |
| Two Hundred Day Average Change Percent | -0.8749912 |
| Type Disp | Equity |
| Volume | 88,920 |
| Website | https://www.geovax.com |
| Zip | 30,080 |